BLUEPRINT - FOR A SUSTAINABLE SUPPLY OF PRESCRIPTION MEDICINES FOR CANADIANS

…II Blueprint for a Sustainable Supply of Prescription Medicines for Canadians EXECUTIVE SUMMARY (CONT'D) • Ensure sustainable pricing levels for biosimilars that reflect the high cost of doing business in Canada compared to other jurisdictions, such as the requirement to fund patient support programs, and the need to support a robust supply of biosimilar medicines for Canadians. [...] …6 Blueprint for a Sustainable Supply of Prescription Medicines for Canadians • Increasing the resiliency and redundancy of the pharmaceutical supply chain, while supporting the continued viability and potential expansion of existing capacity to support domestic and global demand, would be a much more pragmatic and beneficial approach for Canadians than seeking to manufacture all medicines require. [...] Given the diversity in manufacturers’ domestic a) Investing in Canada’s Pharmaceutical Infrastructure production capacity and supply chains, governments • The CGPA is encouraged by the renewed focus of governments in Canada will need to engage on enhancing the capacity of the Canadian prescription drug with individual manufacturers supply and domestic capabilities. [...] Domestic Market for Ensure sustainable pricing levels for biosimilars Biosimilars — that reflect the high cost of doing business in Canada compared to other jurisdictions, such as the Maximize the use of biosimilar requirement to fund patient support programs, and medicines through broad the need to support a robust supply of biosimilar implementation of well- medicines for Canadians. [...] Medicines to Domestically • The federal, provincial and territorial governments and Canada’s Produce and Stockpile for hospital sector must take a coordinated approach to establishing Canadian Needs — a list of essential medicines and then work with the generic pharmaceutical industry to put in place a plan to ensure their The federal, provincial and domestic production and / or import.